Carfilzomib In Newly Diagnosed Multiple Myeloma.pptx
Download as pptx, pdf0 likes56 views
This document discusses the history and current state of treatment for multiple myeloma. It begins with a brief history of treatments from the 1960s including melphalan and prednisone and the introduction of autologous stem cell transplantation in the 1980s. It then focuses on the approval and mechanisms of proteasome inhibitors (PIs) including carfilzomib. Several studies are summarized that show carfilzomib based regimens achieving high rates of stringent complete response and minimal residual disease negativity in both relapsed and newly diagnosed multiple myeloma patients including those with high-risk disease. While cardiac toxicity has been a concern, it is reported to occur in only a low number of patients.
1 of 46
Download to read offline
Ad
Recommended
CRC Case Closed Presentation.pdf
CRC Case Closed Presentation.pdfDevi Seal
油
This document summarizes a presentation on utilizing biomarkers in the management of metastatic colorectal cancer. It discusses three cases involving patients with metastatic colorectal cancer. For the first case, the necessary molecular testing is determined to be testing for all RAS mutations, BRAFV600E, MMR/MSI, and HER2 amplification. For the second case, the next best treatment for a patient with HER2-positive disease is determined to be Trastuzumab + Lapatinib, Trastuzumab + Pertuzumab, or Trastuzumab Deruxtecan. For the third case, the treatment approach depends on whether an NTRK gene fusion is identified.Small Cell Lung Cancer
Small Cell Lung CancerAjay Sasidharan
油
This document summarizes information about small cell lung cancer (SCLC), including its incidence, risk factors, staging, prognosis, diagnostic workup, and treatment approaches. Some key points:
- SCLC accounts for 15-20% of lung cancer cases and has a median age of diagnosis of 64. Most patients are smokers.
- Limited stage SCLC is confined to one lung and nearby lymph nodes, while extensive stage has spread further. Median survival is 25 months for limited vs 9 months for extensive disease.
- Workup includes imaging, biopsy, and brain MRI due to the risk of brain metastases. PET-CT helps determine extent of disease.
- Historically, surgery and chemotherapy alone didNsclc slide deck
Nsclc slide deckPLMMedical
油
This document discusses evolving strategies for the personalized treatment of non-small cell lung cancer (NSCLC). It covers histological and molecular subtypes of NSCLC, key clinical trials of the EGFR tyrosine kinase inhibitor gefitinib, mechanisms of acquired resistance to EGFR TKIs, and approaches to managing resistance. A phase IV study showed gefitinib was effective first-line therapy for Caucasian patients with EGFR mutation-positive NSCLC, with a 69.8% response rate and favorable progression-free and overall survival. Exploratory analyses found plasma samples could accurately assess EGFR mutation status when tumor tissue was unavailable. The document reviews strategies for treating systemic and central nervous system progression after acquiring resistance to EGFR TA Novel Immunohistochemical Signature with the Quantification of HER2 Predict...
A Novel Immunohistochemical Signature with the Quantification of HER2 Predict...Premier Publishers
油
This study evaluated biomarkers that can predict response to neoadjuvant chemotherapy and anti-HER2 therapy in HER2-positive breast cancer patients. The researchers found:
1) HER2 score alone was a poor predictor of response, with an AUC of 0.719 for HER2 score 3+.
2) A novel immunohistochemical signature incorporating high HER2 score 3+, high Ki67, low ER, and no lymph node involvement had an improved AUC of 0.809 for predicting response.
3) Optimal cut-off values for HER2 score 3+ varied by subtype, with 21% for HER2-enriched tumors having the best balance of sensitivity and specificity for predicting response.Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?
Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?Duke Heart
油
The document discusses the need for subspecialization within the genetic cardiomyopathy and sarcoidosis clinic, emphasizing the importance of cause-specific treatments for improving heart failure outcomes. It highlights the multidisciplinary approach required to manage cardiac sarcoidosis and the potential of genetic testing to clarify diagnoses in related inflammatory cardiomyopathies. The content also addresses recent advancements in biomedical innovation, particularly in genetics, suggesting a transformative era in medical research.Newly Diagnosed Myeloma
Newly Diagnosed Myelomaspa718
油
The document summarizes the best approaches to treating newly diagnosed multiple myeloma based on patient fitness level and risk profile. For fit patients, phase 3 trials show superior outcomes with bortezomib-containing triple-drug induction regimens followed by stem cell collection and autologous stem cell transplant compared to doublet regimens. For unfit patients, bortezomib-melphalan-prednisone or lenalidomide-low dose dexamethasone are standard first-line options. High-risk patients with genomic abnormalities may benefit from enrollment in clinical trials or bortezomib-containing consolidation/maintenance therapies with consideration of autologous stem cell transplant.Her2 nact aug 20 - copy
Her2 nact aug 20 - copymadurai
油
- HER2-positive early-stage breast cancer can be treated with neoadjuvant chemotherapy to shrink tumors and increase the rate of breast conservation.
- The addition of trastuzumab to neoadjuvant chemotherapy significantly increases pathological complete response (pCR) rates. Achieving pCR correlates with improved long-term outcomes.
- Adding pertuzumab to trastuzumab and chemotherapy further increases pCR rates compared to chemotherapy and trastuzumab alone. Trials also suggest improved long-term outcomes with dual anti-HER2 blockade.Whats New With HER2: Charting New Paths in NSCLC Care Module 1: HER2 in NSC...
Whats New With HER2: Charting New Paths in NSCLC Care Module 1: HER2 in NSC...i3 Health
油
The document discusses the implications of HER2 mutations in non-small cell lung cancer (NSCLC) care, including actionable insights and recommendations for testing. Key points include the significance of HER2 mutations for treatment planning, methods for detection, and the development of targeted therapies such as trastuzumab deruxtecan in later-line settings. Overall, HER2-activating mutations are highlighted as critical oncogenic drivers in NSCLC, with a particular focus on their genomic profiling and therapeutic applications.Trastuzumab
Trastuzumabmadurai
油
1) The document discusses a symposium on trastuzumab in early breast cancer treatment.
2) Trastuzumab requires HER2 overexpression for efficacy and is associated with improved overall survival when used in the adjuvant setting for breast cancers that overexpress HER2.
3) The symposium included a question and answer session on the appropriate use and efficacy of trastuzumab in breast cancer treatment.Antiangiogenic Therapy in colorectal cancer
Antiangiogenic Therapy in colorectal cancerMohamed Abdulla
油
1) Anti-angiogenic therapy targets tumor angiogenesis and has become an established treatment for metastatic colorectal cancer (mCRC).
2) Bevacizumab, a monoclonal antibody targeting VEGF, has shown efficacy in multiple phase III trials in combination with chemotherapy as first-line and maintenance therapy for mCRC.
3) Additional anti-angiogenic agents approved for mCRC include aflibercept, ramucirumab, and regorafinib, which have demonstrated benefits in later lines of therapy.Sequencing Agents in Metastatic Prostate Cancer
Sequencing Agents in Metastatic Prostate Cancerflasco_org
油
1) The document discusses sequencing agents for metastatic castration-resistant prostate cancer, including trials comparing androgen deprivation therapy alone versus androgen deprivation therapy plus docetaxel chemotherapy.
2) It reviews recent trials of sipuleucel-T, abiraterone, enzalutamide, cabazitaxel, and radium-223 that have shown improved overall survival compared to controls.
3) It discusses potential mechanisms of resistance to these agents, such as AR-V7 splice variants, and investigational agents like niclosamide that may be effective for patients with resistance.Question of Quality Conference 2016 - Personalized Cancer Medicine
Question of Quality Conference 2016 - Personalized Cancer MedicineHCA Healthcare UK
油
This document summarizes a presentation on personalized cancer medicine. It discusses:
1. A brief history of precision oncology, from identifying the Philadelphia chromosome in 1960 to recent advances in immunotherapy.
2. The concept of driver mutations that directly or indirectly confer growth advantages to cancer cells and have clinical implications for diagnosis, prognosis, or targeted therapies.
3. How next-generation sequencing can best identify all four classes of genomic alterations that drive tumor growth by sequencing both DNA and RNA.
4. Some case histories where genomic profiling identified targetable alterations and patients benefited from matched targeted therapies.
5. Concluding thoughts on the complexity of the cancer genome and how comprehensive genomic profiling is enabling evidence-based#HCAQofQ Tariq Mughal
#HCAQofQ Tariq MughalRebecca Pullen
油
Tariq Mughal discusses personalized cancer medicine and highlights some key points:
1. Precision medicine has evolved greatly over the past few decades from basic cytogenetics and hormone therapies to comprehensive genomic profiling and immunotherapy. Targeted therapies are revolutionizing cancer treatment.
2. Driver mutations directly or indirectly confer a growth advantage to cancer cells and have clinical implications for diagnosis, prognosis, and targeted therapies. Comprehensive genomic profiling using next-generation sequencing can best identify all classes of driver mutations.
3. Case histories demonstrate how genomic profiling can identify targetable genomic alterations like ERBB2 mutations, ALK fusions, and FBXW7 mutations and guide treatment with targeted therapies, often with dramatic responses4354 Scc Of Oral Tongue
4354 Scc Of Oral TongueMedicineAndHealthResearch
油
The document presents a matched-pair analysis comparing outcomes of young patients (<45 years old) and older patients (>45 years old) with squamous cell carcinoma of the oral tongue. Younger patients had fewer locoregional recurrences, and better overall and disease-specific survival rates. The study was limited by small sample size but found tentative evidence that tongue cancer in young patients may be a distinct disease influenced by factors like HPV infection rather than tobacco and alcohol use.High Risk Lymphoma
High Risk Lymphomaspa718
油
The document discusses advancements in the treatment of aggressive non-Hodgkin lymphoma (NHL), particularly focusing on the efficacy of autologous stem cell transplantation (ASCT) versus standard chemotherapy. It examines various studies and trials, highlighting that while ASCT can benefit some patients, there is no definitive survival advantage over conventional therapies in certain populations. Additionally, the results emphasize the importance of patient-specific factors and the ongoing debate around the best treatment approach in the context of newer therapies such as rituximab.FrL6M-1.6_slides_download_PPT_Clinical_review_of_nmCRPC_slides_Prof_Steven_Jo...
FrL6M-1.6_slides_download_PPT_Clinical_review_of_nmCRPC_slides_Prof_Steven_Jo...NikolaosDiamantopoul1
油
The document is a clinical review focusing on non-metastatic castration-resistant prostate cancer (nmcrpc), detailing key trials and FDA-approved treatments targeting the condition. It discusses the significance of metastasis-free survival (mfs) as an endpoint in clinical trials and highlights the approvals of apalutamide, enzalutamide, and darolutamide based on their mfs outcomes. Additionally, it addresses the varying safety profiles of these treatments and emphasizes the need for direct comparative trials to assess adverse events.Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016
Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016Mohamed Abdulla
油
The document presents updates on colon cancer, highlighting its prevalence, incidence rates, and risk factors, particularly among younger populations. It discusses treatment strategies, including the effectiveness of aspirin, chemotherapy for various stages, and the impact of genetic markers on therapy choices. Key findings emphasize the evolving landscape of treatment options and the potential significance of treatment sequence over drug exposure in improving patient outcomes.Elderly Acute Myeloid Leukemia
Elderly Acute Myeloid Leukemiaspa718
油
This document summarizes key findings from several studies related to acute myeloid leukemia (AML) in elderly patients:
1) A phase 3 trial found that azacitidine extended overall survival compared to conventional care regimens in older patients with newly diagnosed AML, with median OS of 10.4 months for azacitidine vs 6.5 months for conventional care.
2) Subanalyses found azacitidine provided particularly long OS benefits vs conventional care for patients with poor-risk cytogenetics (median OS 6.4 vs 3.2 months) or myelodysplasia-related changes (1-year OS 55.1% vs 31.3% for LDAC preselectedCancer stem cells &new therapeutics methods
Cancer stem cells &new therapeutics methodsmahdi hatami
油
This document discusses cancer stem cells (CSCs) and new therapeutic approaches to target them. It introduces CSCs, their characteristics like self-renewal and chemoresistance. CSCs can be identified by specific cell surface markers and sphere formation assays. New therapies aim to target CSCs' signaling pathways, surface markers, drug efflux pumps, and microenvironment. Targeting CSCs provides a promising approach for improving cancer treatment outcomes as CSCs are responsible for tumor growth, metastasis, and therapeutic resistance.Cardiac Allograft Vasculopathy in Redo-Transplants- Is It More or Less (or) t...
Cardiac Allograft Vasculopathy in Redo-Transplants- Is It More or Less (or) t...Anya Ragnhildstveit
油
This study examined the relationship between the MELD-XI score and mortality in patients who received an orthotopic heart transplant (OHT). The researchers analyzed data from over 27,000 OHT patients between 2002-2012 from the United Network for Organ Sharing database. They found that 22% of patients had a MELD-XI score over 17 at the time of transplant. Higher MELD-XI scores were associated with significantly lower 30-day, 1-year, and 5-year survival rates compared to those with lower scores. After adjusting for other factors, a high MELD-XI score remained an independent predictor of increased mortality at 30 days, 1 year, and 5 years following OHT. This large study demonstratesMultidisciplinary approach to the management of leukemias aml
Multidisciplinary approach to the management of leukemias amlmadurai
油
The document discusses the multidisciplinary approach to managing leukemias like AML and MDS. It presents the case of a 68-year old male patient presenting with fever and fatigue, and details the diagnostic workup showing features consistent with acute myeloid leukemia. The document then reviews classification, prognostic factors, recent treatment trials, and the role of allogeneic stem cell transplantation for AML patients.Pancreatic cancer (6 October 2014)
Pancreatic cancer (6 October 2014)Zeena Nackerdien
油
The document provides a comprehensive overview of pancreatic cancer, including its epidemiology, risk factors, tumor types, prognosis, mutation frequencies, potential biomarkers, diagnostic tests, and treatment guidelines. It highlights that pancreatic adenocarcinoma is the most common and has a dire prognosis with low survival rates, and outlines various investigational and approved drugs for treatment. Additionally, it discusses the importance of genetic mutations and biomarkers in forming a diagnosis and guiding treatment strategies.Hepatoblastoma- Investigations and management
Hepatoblastoma- Investigations and managementARJUN MANDADE
油
This document summarizes information about hepatoblastoma, a rare type of liver cancer that mostly affects young children. It discusses the history and terminology of hepatoblastoma. Key points include: hepatoblastoma typically affects children under 3 years old and accounts for about 1% of childhood cancers. Complete surgical resection is the main treatment when possible but less than 50% of patients are resectable at diagnosis. The addition of cisplatin-based chemotherapy has improved outcomes by increasing resectability. Prognosis remains suboptimal for patients with unresectable or metastatic disease after chemotherapy. Chemoembolization and liver transplantation are promising alternative treatments in these cases.Metastatic HER2 Garcia.pptx
Metastatic HER2 Garcia.pptxVijayNagThota
油
1) HER2 positive breast cancer accounts for around 15-20% of cases and has a poorer prognosis than other subtypes without HER2 targeted therapy.
2) Multiple HER2 targeted agents are available including trastuzumab, lapatinib, pertuzumab, T-DM1, neratinib, and tucatinib which inhibit HER2 signaling through different mechanisms such as antibody binding or tyrosine kinase inhibition.
3) Combining HER2 targeted therapies such as trastuzumab with chemotherapy improves outcomes for patients with metastatic HER2 positive breast cancer compared to chemotherapy alone.Cancer Discovery-2014-Horwitz-730-43
Cancer Discovery-2014-Horwitz-730-43Elad Horwitz
油
This study identified a recurrent amplification of the VEGFA gene locus in a subset of mouse and human hepatocellular carcinomas (HCC). Tumors with this amplification (Amppos) displayed distinct characteristics including higher proliferation, vessel density, and macrophage content compared to tumors without the amplification (Ampneg). Additionally, Amppos tumors had increased expression of VEGFA and other genes in the amplified region. Treatment with sorafenib, which targets VEGFR, was found to be particularly effective in inhibiting the growth of Amppos HCCs both in mouse models and human patients. This suggests VEGFA amplification could serve as a biomarker to identify HCC patients most likely to benefit from sorafenib or otherSABCS 2024 Roundup: Whats the Latest in Metastatic Breast Cancer (MBC)
SABCS 2024 Roundup: Whats the Latest in Metastatic Breast Cancer (MBC)RheannaRandazzo
油
The SABCS 2024 round-up highlights key advances in metastatic breast cancer treatments, including the use of imlunestrant as monotherapy and with abemaciclib for HR+/HER2-negative cases, and the combination of HER2-targeted therapies for HER2-positive cases. Notably, the EMBER-3 trial demonstrated that imlunestrant leads to improved progression-free survival in patients with ESR1 mutations. Additionally, the PATINA trial aims to evaluate the efficacy of combining palbociclib with anti-HER2 therapies in hormone receptor-positive, HER2-positive metastatic breast cancer.JUNE 2025 ONCOLOGY CARTOONS BY DR KANHU CHARAN PATRO
JUNE 2025 ONCOLOGY CARTOONS BY DR KANHU CHARAN PATROKanhu Charan
油
JUNE 2025 ONCOLOGY CARTOONS BY DR KANHU CHARAN PATROclinical approach to a woman with gynecological problem.ppt
clinical approach to a woman with gynecological problem.pptFaculty of Medicine
油
clinical approach to a woman with gynecological problemUse of Artificial Intelligence in the Management of Osteoporosis
Use of Artificial Intelligence in the Management of OsteoporosisDrOmLakhani1
油
Made by the Human-in-the-loop model using DrPPT.in
The World's first and only autonomous AI agent that can make the best in class Medical Presentations for doctors and other healthcare professionalsHEALTH CARE PLANNING AND ORGANIZATION OF HEALTH CARE
HEALTH CARE PLANNING AND ORGANIZATION OF HEALTH CAREnawaabaquib
油
This PowerPoint presentation covers Unit II: Health Care Planning and Organization of Health Care at Various Levels in a simple and easy-to-understand format. It explains importance of health planning in India. The PPT also includes the structure of the health care system at central, state, and local levels. It is useful for GNM ,BSc And Msc Nursing students. This presentation is also helpful for exam preparation .More Related Content
Similar to Carfilzomib In Newly Diagnosed Multiple Myeloma.pptx (18)
Trastuzumab
Trastuzumabmadurai
油
1) The document discusses a symposium on trastuzumab in early breast cancer treatment.
2) Trastuzumab requires HER2 overexpression for efficacy and is associated with improved overall survival when used in the adjuvant setting for breast cancers that overexpress HER2.
3) The symposium included a question and answer session on the appropriate use and efficacy of trastuzumab in breast cancer treatment.Antiangiogenic Therapy in colorectal cancer
Antiangiogenic Therapy in colorectal cancerMohamed Abdulla
油
1) Anti-angiogenic therapy targets tumor angiogenesis and has become an established treatment for metastatic colorectal cancer (mCRC).
2) Bevacizumab, a monoclonal antibody targeting VEGF, has shown efficacy in multiple phase III trials in combination with chemotherapy as first-line and maintenance therapy for mCRC.
3) Additional anti-angiogenic agents approved for mCRC include aflibercept, ramucirumab, and regorafinib, which have demonstrated benefits in later lines of therapy.Sequencing Agents in Metastatic Prostate Cancer
Sequencing Agents in Metastatic Prostate Cancerflasco_org
油
1) The document discusses sequencing agents for metastatic castration-resistant prostate cancer, including trials comparing androgen deprivation therapy alone versus androgen deprivation therapy plus docetaxel chemotherapy.
2) It reviews recent trials of sipuleucel-T, abiraterone, enzalutamide, cabazitaxel, and radium-223 that have shown improved overall survival compared to controls.
3) It discusses potential mechanisms of resistance to these agents, such as AR-V7 splice variants, and investigational agents like niclosamide that may be effective for patients with resistance.Question of Quality Conference 2016 - Personalized Cancer Medicine
Question of Quality Conference 2016 - Personalized Cancer MedicineHCA Healthcare UK
油
This document summarizes a presentation on personalized cancer medicine. It discusses:
1. A brief history of precision oncology, from identifying the Philadelphia chromosome in 1960 to recent advances in immunotherapy.
2. The concept of driver mutations that directly or indirectly confer growth advantages to cancer cells and have clinical implications for diagnosis, prognosis, or targeted therapies.
3. How next-generation sequencing can best identify all four classes of genomic alterations that drive tumor growth by sequencing both DNA and RNA.
4. Some case histories where genomic profiling identified targetable alterations and patients benefited from matched targeted therapies.
5. Concluding thoughts on the complexity of the cancer genome and how comprehensive genomic profiling is enabling evidence-based#HCAQofQ Tariq Mughal
#HCAQofQ Tariq MughalRebecca Pullen
油
Tariq Mughal discusses personalized cancer medicine and highlights some key points:
1. Precision medicine has evolved greatly over the past few decades from basic cytogenetics and hormone therapies to comprehensive genomic profiling and immunotherapy. Targeted therapies are revolutionizing cancer treatment.
2. Driver mutations directly or indirectly confer a growth advantage to cancer cells and have clinical implications for diagnosis, prognosis, and targeted therapies. Comprehensive genomic profiling using next-generation sequencing can best identify all classes of driver mutations.
3. Case histories demonstrate how genomic profiling can identify targetable genomic alterations like ERBB2 mutations, ALK fusions, and FBXW7 mutations and guide treatment with targeted therapies, often with dramatic responses4354 Scc Of Oral Tongue
4354 Scc Of Oral TongueMedicineAndHealthResearch
油
The document presents a matched-pair analysis comparing outcomes of young patients (<45 years old) and older patients (>45 years old) with squamous cell carcinoma of the oral tongue. Younger patients had fewer locoregional recurrences, and better overall and disease-specific survival rates. The study was limited by small sample size but found tentative evidence that tongue cancer in young patients may be a distinct disease influenced by factors like HPV infection rather than tobacco and alcohol use.High Risk Lymphoma
High Risk Lymphomaspa718
油
The document discusses advancements in the treatment of aggressive non-Hodgkin lymphoma (NHL), particularly focusing on the efficacy of autologous stem cell transplantation (ASCT) versus standard chemotherapy. It examines various studies and trials, highlighting that while ASCT can benefit some patients, there is no definitive survival advantage over conventional therapies in certain populations. Additionally, the results emphasize the importance of patient-specific factors and the ongoing debate around the best treatment approach in the context of newer therapies such as rituximab.FrL6M-1.6_slides_download_PPT_Clinical_review_of_nmCRPC_slides_Prof_Steven_Jo...
FrL6M-1.6_slides_download_PPT_Clinical_review_of_nmCRPC_slides_Prof_Steven_Jo...NikolaosDiamantopoul1
油
The document is a clinical review focusing on non-metastatic castration-resistant prostate cancer (nmcrpc), detailing key trials and FDA-approved treatments targeting the condition. It discusses the significance of metastasis-free survival (mfs) as an endpoint in clinical trials and highlights the approvals of apalutamide, enzalutamide, and darolutamide based on their mfs outcomes. Additionally, it addresses the varying safety profiles of these treatments and emphasizes the need for direct comparative trials to assess adverse events.Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016
Colon Cancer Updates - 2015/2016 - Based on ASCO GI 2016Mohamed Abdulla
油
The document presents updates on colon cancer, highlighting its prevalence, incidence rates, and risk factors, particularly among younger populations. It discusses treatment strategies, including the effectiveness of aspirin, chemotherapy for various stages, and the impact of genetic markers on therapy choices. Key findings emphasize the evolving landscape of treatment options and the potential significance of treatment sequence over drug exposure in improving patient outcomes.Elderly Acute Myeloid Leukemia
Elderly Acute Myeloid Leukemiaspa718
油
This document summarizes key findings from several studies related to acute myeloid leukemia (AML) in elderly patients:
1) A phase 3 trial found that azacitidine extended overall survival compared to conventional care regimens in older patients with newly diagnosed AML, with median OS of 10.4 months for azacitidine vs 6.5 months for conventional care.
2) Subanalyses found azacitidine provided particularly long OS benefits vs conventional care for patients with poor-risk cytogenetics (median OS 6.4 vs 3.2 months) or myelodysplasia-related changes (1-year OS 55.1% vs 31.3% for LDAC preselectedCancer stem cells &new therapeutics methods
Cancer stem cells &new therapeutics methodsmahdi hatami
油
This document discusses cancer stem cells (CSCs) and new therapeutic approaches to target them. It introduces CSCs, their characteristics like self-renewal and chemoresistance. CSCs can be identified by specific cell surface markers and sphere formation assays. New therapies aim to target CSCs' signaling pathways, surface markers, drug efflux pumps, and microenvironment. Targeting CSCs provides a promising approach for improving cancer treatment outcomes as CSCs are responsible for tumor growth, metastasis, and therapeutic resistance.Cardiac Allograft Vasculopathy in Redo-Transplants- Is It More or Less (or) t...
Cardiac Allograft Vasculopathy in Redo-Transplants- Is It More or Less (or) t...Anya Ragnhildstveit
油
This study examined the relationship between the MELD-XI score and mortality in patients who received an orthotopic heart transplant (OHT). The researchers analyzed data from over 27,000 OHT patients between 2002-2012 from the United Network for Organ Sharing database. They found that 22% of patients had a MELD-XI score over 17 at the time of transplant. Higher MELD-XI scores were associated with significantly lower 30-day, 1-year, and 5-year survival rates compared to those with lower scores. After adjusting for other factors, a high MELD-XI score remained an independent predictor of increased mortality at 30 days, 1 year, and 5 years following OHT. This large study demonstratesMultidisciplinary approach to the management of leukemias aml
Multidisciplinary approach to the management of leukemias amlmadurai
油
The document discusses the multidisciplinary approach to managing leukemias like AML and MDS. It presents the case of a 68-year old male patient presenting with fever and fatigue, and details the diagnostic workup showing features consistent with acute myeloid leukemia. The document then reviews classification, prognostic factors, recent treatment trials, and the role of allogeneic stem cell transplantation for AML patients.Pancreatic cancer (6 October 2014)
Pancreatic cancer (6 October 2014)Zeena Nackerdien
油
The document provides a comprehensive overview of pancreatic cancer, including its epidemiology, risk factors, tumor types, prognosis, mutation frequencies, potential biomarkers, diagnostic tests, and treatment guidelines. It highlights that pancreatic adenocarcinoma is the most common and has a dire prognosis with low survival rates, and outlines various investigational and approved drugs for treatment. Additionally, it discusses the importance of genetic mutations and biomarkers in forming a diagnosis and guiding treatment strategies.Hepatoblastoma- Investigations and management
Hepatoblastoma- Investigations and managementARJUN MANDADE
油
This document summarizes information about hepatoblastoma, a rare type of liver cancer that mostly affects young children. It discusses the history and terminology of hepatoblastoma. Key points include: hepatoblastoma typically affects children under 3 years old and accounts for about 1% of childhood cancers. Complete surgical resection is the main treatment when possible but less than 50% of patients are resectable at diagnosis. The addition of cisplatin-based chemotherapy has improved outcomes by increasing resectability. Prognosis remains suboptimal for patients with unresectable or metastatic disease after chemotherapy. Chemoembolization and liver transplantation are promising alternative treatments in these cases.Metastatic HER2 Garcia.pptx
Metastatic HER2 Garcia.pptxVijayNagThota
油
1) HER2 positive breast cancer accounts for around 15-20% of cases and has a poorer prognosis than other subtypes without HER2 targeted therapy.
2) Multiple HER2 targeted agents are available including trastuzumab, lapatinib, pertuzumab, T-DM1, neratinib, and tucatinib which inhibit HER2 signaling through different mechanisms such as antibody binding or tyrosine kinase inhibition.
3) Combining HER2 targeted therapies such as trastuzumab with chemotherapy improves outcomes for patients with metastatic HER2 positive breast cancer compared to chemotherapy alone.Cancer Discovery-2014-Horwitz-730-43
Cancer Discovery-2014-Horwitz-730-43Elad Horwitz
油
This study identified a recurrent amplification of the VEGFA gene locus in a subset of mouse and human hepatocellular carcinomas (HCC). Tumors with this amplification (Amppos) displayed distinct characteristics including higher proliferation, vessel density, and macrophage content compared to tumors without the amplification (Ampneg). Additionally, Amppos tumors had increased expression of VEGFA and other genes in the amplified region. Treatment with sorafenib, which targets VEGFR, was found to be particularly effective in inhibiting the growth of Amppos HCCs both in mouse models and human patients. This suggests VEGFA amplification could serve as a biomarker to identify HCC patients most likely to benefit from sorafenib or otherSABCS 2024 Roundup: Whats the Latest in Metastatic Breast Cancer (MBC)
SABCS 2024 Roundup: Whats the Latest in Metastatic Breast Cancer (MBC)RheannaRandazzo
油
The SABCS 2024 round-up highlights key advances in metastatic breast cancer treatments, including the use of imlunestrant as monotherapy and with abemaciclib for HR+/HER2-negative cases, and the combination of HER2-targeted therapies for HER2-positive cases. Notably, the EMBER-3 trial demonstrated that imlunestrant leads to improved progression-free survival in patients with ESR1 mutations. Additionally, the PATINA trial aims to evaluate the efficacy of combining palbociclib with anti-HER2 therapies in hormone receptor-positive, HER2-positive metastatic breast cancer.FrL6M-1.6_slides_download_PPT_Clinical_review_of_nmCRPC_slides_Prof_Steven_Jo...
FrL6M-1.6_slides_download_PPT_Clinical_review_of_nmCRPC_slides_Prof_Steven_Jo...NikolaosDiamantopoul1
油
Cardiac Allograft Vasculopathy in Redo-Transplants- Is It More or Less (or) t...
Cardiac Allograft Vasculopathy in Redo-Transplants- Is It More or Less (or) t...Anya Ragnhildstveit
油
Recently uploaded (20)
JUNE 2025 ONCOLOGY CARTOONS BY DR KANHU CHARAN PATRO
JUNE 2025 ONCOLOGY CARTOONS BY DR KANHU CHARAN PATROKanhu Charan
油
JUNE 2025 ONCOLOGY CARTOONS BY DR KANHU CHARAN PATROclinical approach to a woman with gynecological problem.ppt
clinical approach to a woman with gynecological problem.pptFaculty of Medicine
油
clinical approach to a woman with gynecological problemUse of Artificial Intelligence in the Management of Osteoporosis
Use of Artificial Intelligence in the Management of OsteoporosisDrOmLakhani1
油
Made by the Human-in-the-loop model using DrPPT.in
The World's first and only autonomous AI agent that can make the best in class Medical Presentations for doctors and other healthcare professionalsHEALTH CARE PLANNING AND ORGANIZATION OF HEALTH CARE
HEALTH CARE PLANNING AND ORGANIZATION OF HEALTH CAREnawaabaquib
油
This PowerPoint presentation covers Unit II: Health Care Planning and Organization of Health Care at Various Levels in a simple and easy-to-understand format. It explains importance of health planning in India. The PPT also includes the structure of the health care system at central, state, and local levels. It is useful for GNM ,BSc And Msc Nursing students. This presentation is also helpful for exam preparation .Diabetes Mellitus Chapter 3 | Pathophysiology, Complications & Management
Diabetes Mellitus Chapter 3 | Pathophysiology, Complications & ManagementPKLI-Institute of Nursing and Allied Health Sciences Lahore , Pakistan.
油
This presentation offers a comprehensive overview of Diabetes Mellitus based on Chapter 3 of standard medical texts. It covers the classification (Type 1, Type 2, GDM), metabolic disturbances, acute complications (DKA, HHS, hypoglycemia), and chronic complications (retinopathy, nephropathy, neuropathy, diabetic foot, infections, macrovascular disease).
Designed for nursing, medical, and allied health students, this slide deck highlights key points on pathophysiology, clinical signs, diagnostic criteria, pharmacologic and non-pharmacologic management, and preventive care strategies.
Clear and structured format
Helpful for academic presentations and exam prep
Suitable for BSN, Post-RN, and healthcare educatorsWinning GAMBITS Against AML: Guidance on Advances & Medical Breakthroughs wit...
Winning GAMBITS Against AML: Guidance on Advances & Medical Breakthroughs wit...PVI, PeerView Institute for Medical Education
油
Chair and Presenter, Naval Daver, MD, Jessica K. Altman, MD, and Ghayas Issa, MD, Alice S. Mims, MD, MSCR, discuss acute myeloid leukemia in this CME/MOC/AAPA/IPCE activity titled Winning GAMBITS Against AML: Guidance on Advances & Medical Breakthroughs with Innovative Targeted Strategies. For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/42f1QCa. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.Global Harmonization Task Force (GHTF) and International Medical Device Regul...
Global Harmonization Task Force (GHTF) and International Medical Device Regul...Arpan Das
油
The Global Harmonization Task Force (GHTF) was a partnership between regulatory authorities and the medical device industry.油It was established in 1992 to improve patient safety and increase access to medical technologies.
The GHTF was replaced by the International Medical Devices Regulators Forum (IMDRF) in 2012. These devices vary widely in type and are highly essential for patients care, their manufacture, distribution, and sale must be regulated to ensure their quality, safety,油and油efficacy.Aspirin powder or Acetyl salicylic acid powder.docx
Aspirin powder or Acetyl salicylic acid powder.docxkopalsharma85
油
pharmacy exercise on aspirin powderDrmohamedaslam_resident_copd2025_fm.pptx
Drmohamedaslam_resident_copd2025_fm.pptxAslam
油
COPD :LATEST GUIDELINES 2025
REFERENCE: Harrisons Principles of Internal Medicine
GOLD -2025 Guidelines
It highlights updated diagnostic criteria, pharmacological and non-pharmacological treatment options, and current best practices for resident doctors and healthcare professionals.
Ideal for medical students, residents, and practitioners seeking an up-to-date, evidence-based reference.
Download, share, and feel free to reach out for related study material!Air Pollution, air quality index, Nepal air pollution
Air Pollution, air quality index, Nepal air pollutionDr. Anu Marhatta
油
This presentation slides is only for educational purposes. Quality by Design Tools in Pharmaceutical Manufacturing Technology
Quality by Design Tools in Pharmaceutical Manufacturing Technology39KomalZaveri
油
In Qbd why risk assessment needed that explained
Design Space and DoE relationship with each other.
Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on...
Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on...PVI, PeerView Institute for Medical Education
油
Co-Chairs, Prof. Dr. Patrick Sch旦ffski, MPH, and Breelyn A. Wilky, MD, discuss desmoid tumors in this CME activity titled Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on Gamma Secretase Inhibitors for Progressive Disease. For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/4iDPUQY. CME credit will be available until June 29, 2026.RCC Treatment Innovations in Practice: Preparing for Individualized Patient Care
RCC Treatment Innovations in Practice: Preparing for Individualized Patient CarePVI, PeerView Institute for Medical Education
油
Chair, Sumanta Kumar Pal, MD, FASCO, David F. McDermott, MD, and Tian Zhang, MD, MHS, prepared useful Practice Aids pertaining to renal cell carcinoma for this CME/MOC/AAPA/IPCE activity titled RCC Treatment Innovations in Practice: Preparing for Individualized Patient Care. For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/4brGF4h. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.nanoparticle and liposomes ppt .(NTDS)pdf
nanoparticle and liposomes ppt .(NTDS)pdfsiddhikalbande
油
Nanoparticles and liposomes are advanced carriers used for targeted drug delivery.
Nanoparticles enhance drug effectiveness by directing treatment to specific sites.
Liposomes are biocompatible vesicles that enable controlled and sustained drug release.Anesthetic Evaluation & Management in Pregnancy with APH.pdf
Anesthetic Evaluation & Management in Pregnancy with APH.pdfDr Anik Roy Chowdhury
油
Dr. Anik Roy Chowdhury
MBBS, BCS (Health), DA, MD Resident
Shaheed Suhrawardy Medical College Hospital (ShSMCH)Severe Acute Respiratory Syndrome (SARS)
Severe Acute Respiratory Syndrome (SARS)Dr. Anu Marhatta
油
This slide is for educational purposes only. Diabetes Mellitus Chapter 3 | Pathophysiology, Complications & Management
Diabetes Mellitus Chapter 3 | Pathophysiology, Complications & ManagementPKLI-Institute of Nursing and Allied Health Sciences Lahore , Pakistan.
油
Winning GAMBITS Against AML: Guidance on Advances & Medical Breakthroughs wit...
Winning GAMBITS Against AML: Guidance on Advances & Medical Breakthroughs wit...PVI, PeerView Institute for Medical Education
油
Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on...
Patient-Centric Frameworks in Desmoid Tumors: Integrating Emerging Science on...PVI, PeerView Institute for Medical Education
油
RCC Treatment Innovations in Practice: Preparing for Individualized Patient Care
RCC Treatment Innovations in Practice: Preparing for Individualized Patient CarePVI, PeerView Institute for Medical Education
油
Ad
Carfilzomib In Newly Diagnosed Multiple Myeloma.pptx
- 1. CARFILZOMIB BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA Dr Kunal Chhattani, Clinical Hematologist, Nagpur
- 2. HISTORY OF MULTIPLE MYELOMA TREATMENT In the 1960s,oral melphalan, an alkylating agent, in combination with prednisone was considered the frontline treatment for MM -Hoogstraten, B.; Sheehe, P.R.; Cuttner, J.; Cooper, T.; Kyle, R.A.; Oberfield, R.A.; Townsend, S.R.; Harley, J.B.; Hayes, D.M.; Costa, G.; et al. Melphalan in multiple myeloma. Blood 1967, 30, 7483
- 3. In the 1980s, autologous stem cell transplantation (ASCT) followed by a high dose of therapy was introduced. -Osserman, E.F.; DiRe, L.B.; DiRe, J.; Sherman, W.H.; Hersman, J.A.; Storb, R. Identical twin marrow transplantation in multiple myeloma. Acta Haematol. 1982, 68, 215223.
- 4. FDA APPROVALS OF PIS -Past, Present, and a Glance into the Future of Multiple Myeloma Treatment Weam Othman Elbezanti et al 2023
- 5. MECHANISM OF ACTION OF PIS Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. Weam Othman Elbezanti et.al, March 23.
- 6. CURRENT STANDARD OF CARE FOR NDMM RVD TRIPLET, SWOG S0777 TRIAL
- 7. RVD APPROVAL FRONTLINE- SWOG S0777 TRIAL
- 9. CARFILZOMIB IN RELAPSED MYELOMA- ASPIRE TRIAL,2015
- 10. CARFILZOMIB IN RELAPSED MYELOMA- ASPIRE TRIAL
- 12. CARFILZOMIB IN TREATMENT NAVE NDMM PATIENTS
- 13. JAKUBOWIAK ET AL 2012
- 19. 33% of patients had Unfavourable Cytogenetics 45% sCR rate after 4 cycles. 24 months PFS- 92%.
- 20. JASEILEC ET AL , 2020
- 27. 60 months PFS- 72% and OS- 84% High risk cytogenetics- 57% and 72% respectively MRD negativity -60% after 8 cycles Grade III and IV cardiac events 3%
- 28. ROUSELL ET. AL. 2021 ASH
- 33. Median PFS -56months and median OS not reached High rates of MRD negativity even after induction
- 34. FORTE TRIAL 2018
- 35. 474 NDMM pts were randomized (KRd_ASCT, n=158; KRd12, n=157; KCd_ASCT, n=159).
- 37. KRD ASCT > KRD > KCD ASCT
- 38. RVD Vs KRD Head to head- Endurance trial 2020
- 43. No significant difference between KRD and RVD without HSCT. Trial excluded High risk Patients
- 44. LIST OF STUDIES DOCUMENTING MRD Current Main Topics in Multiple Myeloma
- 45. FOR CARFILZOMIB Deeper and quicker responses- high rate of sCR rates post induction High rate of MRD negativity in trials Activity against High risk myeloma Cardiac toxicity , though of caution, is seen in low number of patients. Deeper responses can be cost effective in long run.
- 46. Thank You!!!